Clover Biopharmaceuticals (HKG:2197) received clearance from the US Food and Drug Administration for its RSV vaccine candidate, SCB-1019, with enrollment completed in the Phase I revaccination clinical trial, according to a filing with the Hong Kong bourse on Monday.
SCB-1019 is a new RSV vaccine using Trimer-Tag technology. It is designed to boost immunity in older adults aged 60 to 85 who previously received an initial dose of GSK's RSV vaccine.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。